KR20020069324A - 비피도박테리움 유래 신규 플라스미드, 이를 이용한재조합 발현 벡터 및 형질전환 방법 - Google Patents
비피도박테리움 유래 신규 플라스미드, 이를 이용한재조합 발현 벡터 및 형질전환 방법 Download PDFInfo
- Publication number
- KR20020069324A KR20020069324A KR1020010009526A KR20010009526A KR20020069324A KR 20020069324 A KR20020069324 A KR 20020069324A KR 1020010009526 A KR1020010009526 A KR 1020010009526A KR 20010009526 A KR20010009526 A KR 20010009526A KR 20020069324 A KR20020069324 A KR 20020069324A
- Authority
- KR
- South Korea
- Prior art keywords
- bifidobacterium
- gene
- vector
- plasmid
- shuttle vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 115
- 239000013612 plasmid Substances 0.000 title claims abstract description 64
- 238000011426 transformation method Methods 0.000 title claims abstract description 9
- 239000013604 expression vector Substances 0.000 title abstract description 3
- 238000003259 recombinant expression Methods 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 80
- 239000013605 shuttle vector Substances 0.000 claims abstract description 70
- 241000588724 Escherichia coli Species 0.000 claims abstract description 39
- 239000002773 nucleotide Substances 0.000 claims abstract description 25
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 25
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 7
- 101150066583 rep gene Proteins 0.000 claims abstract description 7
- 239000013598 vector Substances 0.000 claims description 76
- 230000009466 transformation Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108010065511 Amylases Proteins 0.000 claims description 13
- 229960000723 ampicillin Drugs 0.000 claims description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 10
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 7
- 230000001766 physiological effect Effects 0.000 claims description 4
- 229930027917 kanamycin Natural products 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 241000131482 Bifidobacterium sp. Species 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 14
- 238000011161 development Methods 0.000 abstract description 5
- 235000013373 food additive Nutrition 0.000 abstract description 5
- 239000002778 food additive Substances 0.000 abstract description 5
- 229940126578 oral vaccine Drugs 0.000 abstract description 5
- 239000006041 probiotic Substances 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 29
- 239000004310 lactic acid Substances 0.000 description 16
- 235000014655 lactic acid Nutrition 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 101000946719 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Carboxysome assembly protein CcmN Proteins 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 101000946720 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Carboxysome assembly protein CcmO Proteins 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 102000013142 Amylases Human genes 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 235000019418 amylase Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000006872 mrs medium Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 4
- 108010052764 Fructose-6-phosphate phosphoketolase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 3
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000007621 bhi medium Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 235000020299 breve Nutrition 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010052444 Oxyrase Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710120698 Plasmid recombination enzyme Proteins 0.000 description 2
- 101710172458 Plasmid recombination enzyme type 2 Proteins 0.000 description 2
- 101710172457 Plasmid recombination enzyme type 3 Proteins 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000186013 Bifidobacterium asteroides Species 0.000 description 1
- 241000186160 Bifidobacterium pseudolongum subsp. globosum Species 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
플라스미드(kb) 숙주 세포 벡터 선별 유전자 |
pMB1(1.9) 비피도박테리움 롱검 pRM2 스펙티노마이신(spectinomycin)a암피실린(ampicillin)bpNC7 클로람페니콜(chloramphenicol)a암피실린bpKJ36(3.6) 비피도박테리움 롱검 KJ pEKJ36 클로람페니콜a암피실린bpKJ50(5.0) 비피도박테리움 롱검 KJ pBKJ50F 클로람페니콜a,bpBKJ50R 클로람페니콜a,bpBRepApNBb1(5.6) 비피도박테리움 브레베 개발되지 않았음pTB6(3.6) 비피도박테리움 롱검 pBLES100 스트랩토마이신(streptomycin)a암피실린b |
Claims (15)
- 서열번호 1로 표시되는 염기서열을 갖는 플라스미드 pMG1.
- 제 1항의 플라스미드를 포함하는 균주 비피도박테리움 롱검 MG1(Bifidobacterium longumMG1)(기탁번호 KFCC-11273).
- 대장균 및 비피도박테리움에서 상호 복제되며서열번호 2로 표시되는 염기서열을 갖는Mob유전자,서열번호 3으로 표시되는 염기서열을 갖는Rep유전자 및 선별 유전자를 포함하는 셔틀벡터.
- 제 3항에 있어서, 상기 셔틀벡터는 제 1항의 플라스미드 pMG1과 대장균 유래 형질전환용 벡터를 이용하여 제조되는 것을 특징으로 하는 셔틀벡터.
- 제 4항에 있어서, 상기 대장균 유래 형질전환용 벡터가 pEK104, pUC19 및 pBR322로 이루어진 군에서 선택되는 어느 하나인 것을 특징으로 하는 셔틀벡터.
- 제 1항의 플라스미드 pMG1과 pEK104를 이용하여 제조된 셔틀벡터 pBES2.
- 제 3항에 있어서, 선별 유전자는 암피실린(ampicillin) 저항성 유전자, 가나마이신(kanamycin) 저항성 유전자 및 클로람페니콜 아세틸 트랜스퍼라아제(chloramphenicol acetyl transferase) 유전자로 이루어진 군에서 선택되는 하나 이상인 것을 특징으로 하는 셔틀벡터.
- 제 3항의 셔틀벡터에 목적 단백질을 코딩하는 목적 유전자를 삽입한 재조합 벡터.
- 제 8항에 있어서, 상기 목적 유전자는 아밀라아제 유전자, 백신유전자, 항암유전자 및 다양한 생리활성을 나타낼 수 있는 유전자로 이루어진 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 재조합 벡터.
- 제 8항의 셔틀벡터에 목적 유전자로 아밀라아제 유전자를 삽입한 재조합 벡터 pYBamy59.
- 제 8항의 재조합 벡터로 형질전환된 형질전환체.
- 제 10항의 재조합 벡터 pYBamy59로 형질전환된 비피도박테리움 롱검 MG1(기탁번호 KFCC-11274).
- 비피도박테리움 유래 플라스미드와 대장균 유래 플라스미드를 이용하여 비피도박테리움과 대장균에서 상호 복제되는 셔틀벡터를 제조하는 단계;상기 셔틀벡터에 목적 단백질을 코딩하는 목적 유전자를 결합시켜 재조합 벡터를 제조하는 단계; 및상기 제조된 재조합 벡터로 형질전환시키기 위한 숙주세포로서 상기 셔틀벡터의 제조에 이용된 비피도박테리움을 이용하는 것을 특징으로 하는 형질전환 방법.
- 서열번호 4로 표시되는 염기서열을 갖는 비피도박테리움 GE65(Bifidobacterium sp. GE65)의 프로모터.
- 서열번호 5로 표시되는 염기서열을 갖는 비피도박테리움 GE65의 프로모터.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0009526A KR100457879B1 (ko) | 2001-02-24 | 2001-02-24 | 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법 |
EP01917936A EP1319080A4 (en) | 2001-02-24 | 2001-03-30 | PLASMID FROM BIFIDOBACTERIUM, RECOMBINANT EXPRESSION VECTOR USING THE SAME, AND PROCESSING METHOD |
PCT/KR2001/000527 WO2002068662A1 (ko) | 2001-02-24 | 2001-03-30 | Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method |
JP2002568756A JP2004519236A (ja) | 2001-02-24 | 2001-03-30 | ビフィドバクテリウム由来の新規なプラスミド、これを利用した組換え発現ベクターおよび形質転換方法 |
US10/258,440 US6887702B2 (en) | 2001-02-24 | 2001-03-30 | Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0009526A KR100457879B1 (ko) | 2001-02-24 | 2001-02-24 | 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2004-0057847A Division KR100483934B1 (ko) | 2004-07-23 | 2004-07-23 | 비피도박테리움 롱검 mg1 유래 신규 플라스미드를 함유하는 셔틀벡터 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020069324A true KR20020069324A (ko) | 2002-08-30 |
KR100457879B1 KR100457879B1 (ko) | 2004-11-18 |
Family
ID=19706236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0009526A Expired - Fee Related KR100457879B1 (ko) | 2001-02-24 | 2001-02-24 | 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법 |
Country Status (5)
Country | Link |
---|---|
US (1) | US6887702B2 (ko) |
EP (1) | EP1319080A4 (ko) |
JP (1) | JP2004519236A (ko) |
KR (1) | KR100457879B1 (ko) |
WO (1) | WO2002068662A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220104535A (ko) | 2021-01-18 | 2022-07-26 | 김기혁 | 후라이드 치킨 제조방법 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867714B1 (en) | 2005-04-08 | 2013-09-18 | Anaeropharma Science Inc. | 5-fluorouracil-resistant bacteria and method for production thereof |
AU2006282722A1 (en) * | 2005-08-26 | 2007-03-01 | Cerenis Therapeutics Holdings S.A. | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
CA2684923C (en) | 2007-05-02 | 2015-01-06 | Merial Limited | Dna plasmids having improved expression and stability |
US9730968B2 (en) | 2008-04-17 | 2017-08-15 | Anaeropharma Science, Inc. | Therapeutic agent for ischemic diseases |
ES2628378T3 (es) * | 2008-04-17 | 2017-08-02 | Anaeropharma Science, Inc. | Vector plasmídico |
EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
KR101850162B1 (ko) * | 2010-01-29 | 2018-04-18 | 가부시키가이샤 아네로파마·사이엔스 | 형질전환용 플라스미드 |
-
2001
- 2001-02-24 KR KR10-2001-0009526A patent/KR100457879B1/ko not_active Expired - Fee Related
- 2001-03-30 JP JP2002568756A patent/JP2004519236A/ja active Pending
- 2001-03-30 EP EP01917936A patent/EP1319080A4/en not_active Withdrawn
- 2001-03-30 WO PCT/KR2001/000527 patent/WO2002068662A1/ko not_active Application Discontinuation
- 2001-03-30 US US10/258,440 patent/US6887702B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220104535A (ko) | 2021-01-18 | 2022-07-26 | 김기혁 | 후라이드 치킨 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
WO2002068662A8 (ko) | 2002-09-26 |
US6887702B2 (en) | 2005-05-03 |
WO2002068662A1 (ko) | 2002-09-06 |
KR100457879B1 (ko) | 2004-11-18 |
EP1319080A1 (en) | 2003-06-18 |
EP1319080A4 (en) | 2004-10-20 |
US20040014221A1 (en) | 2004-01-22 |
JP2004519236A (ja) | 2004-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Matteuzzi et al. | Bifidobacterium suis n. sp.: A new species of the genus Bifidobacterium isolated from pig faces | |
EA017558B1 (ru) | ШТАММ БАКТЕРИЙ Е.Mundtii ST4SA, СПОСОБНЫЙ ПРОДУЦИРОВАТЬ АНТИБАКТЕРИАЛЬНЫЙ ПЕПТИД ST4SA, СПОСОБ ПОЛУЧЕНИЯ ПЕПТИДА ST4SA И ПРИМЕНЕНИЕ ШТАММА БАКТЕРИЙ Е.Mundtii ST4SA И ПЕПТИДА | |
US8741622B2 (en) | Stress tolerant Bifidobacteria | |
WO2016125861A1 (ja) | 乳酸菌、該乳酸菌由来の自然免疫活性化剤、感染症予防治療剤及び飲食品 | |
KR100457879B1 (ko) | 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법 | |
JPH09269A (ja) | 乳酸菌産生エキソポリサッカライド | |
AU753558B2 (en) | Production of L(+)-Lactate | |
JPH10503643A (ja) | 微生物中に遺伝物質を導入する方法およびその方法によってえられる形質転換体 | |
JP3620831B2 (ja) | 乳酸菌シャトルベクター | |
KR20040072545A (ko) | 비피도박테리움 롱검 mg1 유래 신규 플라스미드를함유하는 셔틀벡터 | |
CN103732742B (zh) | 赋予过氧化氢耐性的基因及其利用 | |
WO2022006748A1 (en) | Genetically engineered live bacteria and methods of constructing the same | |
KR100621657B1 (ko) | 내산성과 내담즙성이 좋고 효소의 생산이 우수한 신규바실러스 서브틸리스 유비티-엠02 균주 , 이 신규 균주를이용 함유하는 사료첨가제 및 이 사료첨가제를 함유하는가축 사료 | |
EP2057266B2 (en) | Genetic remodeling in bifidobacterium | |
WO2005001068A1 (en) | A BIFIDOBACTERIUM BREVE LMC520 STRAIN CONTAINING A PLASMID Pbc520, A METHOD FOR PREPARATION OF CONJUGATED FATTY ACIDS AND FERMENTED MILKS CONTAINING SUCH FATTY ACIDS USING THE SAME STRAIN, AND USE OF A PLASMID pBC520 | |
KR100804193B1 (ko) | 락타아제를 생산하는 신균주 락토바실러스 아시도필러스la-12 | |
KR0157757B1 (ko) | 내산성 및 내담즙성 비피도박테리움의 분리방법 | |
Zaman et al. | Isolation and characterization of potential probiotic bacteria from Sahiwal cow gut | |
KR100357237B1 (ko) | 한우 유래 락토페린 발현용 재조합 효모균주 및 이로부터 얻은 재조합 락토페린 | |
WO2024204681A1 (ja) | ビフィドバクテリウム属細菌の形質転換方法 | |
CN117264973A (zh) | 一种乳酸菌表面蛋白过表达体系构建和应用 | |
Kimoto-Nira et al. | Factors for bile tolerance in Lactococcus lactis: analysis by using plasmid variants | |
JPH02312590A (ja) | プラスミドpTY1 | |
WO2002036756A2 (fr) | Souche de lactobacillus sakei, et plasmide heberge par ladite souche | |
KR20030010879A (ko) | 비피도박테리움 아돌레센티스에서 분리된 β-갈락토시다제유전자 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20010224 |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20010228 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20010224 Comment text: Patent Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20031016 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20040527 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20031016 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
J201 | Request for trial against refusal decision | ||
PJ0201 | Trial against decision of rejection |
Patent event date: 20040625 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20040527 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20040811 Appeal identifier: 2004101002829 Request date: 20040625 |
|
A107 | Divisional application of patent | ||
AMND | Amendment | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20040723 Patent event code: PA01071R01D |
|
PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20040723 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20040625 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20031215 Patent event code: PB09011R02I |
|
B701 | Decision to grant | ||
PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20040811 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20040805 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20041110 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20041111 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20071025 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20081024 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20090821 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20101006 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20111103 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20111103 Start annual number: 8 End annual number: 8 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |